Digital Microbiome Analysis
By encapsulating cells in gel capsules for nucleic acid amplification and digital counting, the method addresses issues of varying gene copy numbers and amplification bias in microbial analysis, achieving accurate microbial composition evaluation.
Patent Information
- Application Number
- JP2021516285
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-04-26
- Filing Date
- 2020-04-24
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2040-04-24
AI Technical Summary
Current methods for analyzing microbial flora composition using amplicon sequence analysis of 16S rRNA genes face challenges such as varying copy numbers of the gene across bacteria, amplification bias during PCR, and difficulty in accurately determining the absolute number of microorganisms, especially those with low composition ratios.
A method that involves encapsulating cells in droplets, gelling them to form gel capsules, lysing the cells, and amplifying nucleic acids within these capsules to enable digital counting of microbial species at the single-cell level, allowing for accurate determination of absolute microbial composition.
This approach allows for the precise evaluation of microbial compositions by overcoming amplification bias and varying copy numbers, enabling accurate counting of microorganisms, even those with low ratios, and providing a more reliable assessment of microbial abundance.
Smart Images

Figure 0007584800000002 
Figure 0007584800000003 
Figure 0007584800000004
Abstract
Description
[Technical field]
[0001] The present disclosure relates to the analysis of microbiota composition and can be used in fields such as biological research, medicine, the environment, and health care. [Background technology]
[0002] In recent years, amplicon sequencing analysis using next-generation sequencers targeting conserved regions of 16SrRNA genes and 18SrRNA genes has been widely used as a method for evaluating the diversity of environmental microorganisms. When targeting the 16SrRNA gene, conserved regions of several hundred bases are PCR-amplified from DNA extracted collectively from samples containing a variety of microorganisms (feces, soil, seawater, etc.), and the base sequences of the conserved regions are comprehensively analyzed using a next-generation sequencer, allowing the composition of the microbiota to be evaluated as the type of base sequence = the type of microbial species. However, this method has several problems.
[0003] First, the number of copies of the 16SrRNA gene on the genome varies from bacteria to bacteria. Some bacteria have only a single copy of the 16SrRNA gene, while others have seven or more copies. Furthermore, since the genomes of most environmental microorganisms have not yet been determined, the number of genes in question is unknown and cannot be corrected.
[0004] Secondly, there is a problem of amplification bias during PCR. In the PCR amplification, the amplification is performed on the conserved region, but since the internal sequence differs for each microorganism, the amplification efficiency differs for each microorganism due to differences in base sequence, etc. As a result, the bias resulting from the difference in amplification efficiency increases as the number of PCR amplification cycles increases. For the above reasons, the composition ratio of the gene sequence finally detected after PCR amplification does not reflect the actual bacterial composition ratio. In addition, since such amplicon sequence analysis only obtains the composition ratio, the actual increase or decrease in the total amount of microorganisms is unknown. In other words, even if a phenomenon is found in which microorganism X is less than other microorganisms by comparing certain samples, it is possible that the total amount of microorganism X has decreased, or that the number of other microorganisms has simply increased and the number of microorganism X has not changed.
[0005] Furthermore, in many microbiome analyses, microorganisms with a composition ratio of 1% or less are grouped together and discussed as "others," but considering the above bias, there is a concern that the microbial composition is estimated to be higher or lower than it actually is. As a solution to this problem, there is a method of using DNA with a known sequence as an internal standard, spiking this into the sample and performing PCR (Non-Patent Document 1 (Stammler et al., 2016 Microbiome, 4(1), 28)), and a method of counting and correcting the absolute number of bacteria using a different method. In the former, it is possible to make a relative comparison of the total number of microorganisms for each sample by comparing the total amount of read sequences with the internal standard, but problems with PCR amplification remain, and it is not possible to count the absolute number of various types of bacteria. In the latter, Non-Patent Document 2 (Vandeputte et al. 2017 Nature) introduces a method of quantitatively evaluating the number of various types of bacteria by counting the absolute number of bacteria using flow cytometry and correcting for the representative 16SrRNA gene copy number of each microbial species. This method involves correction using a representative value, and there are problems with the accuracy of the method, such as the existence of microorganisms for which the copy number cannot be accurately estimated, the fact that the samples used to measure the bacterial count and the samples used for sequence analysis are essentially separate, and the fact that it is generally difficult to count tiny microorganisms separately from non-cellular particles using flow cytometry. [Prior art documents] [Non-patent literature]
[0006] [Non-Patent Document 1] Stammler et al., 2016 Microbiome, 4(1), 28 [Non-Patent Document 2] Vandeputte et al. 2017 Nature, 551(7681), 507-511 Summary of the Invention [Means for solving the problem]
[0007] As a result of intensive research, the inventors have discovered that a method for analyzing microbiota composition, which includes a step of evaluating the microbiota composition from a sample containing amplified nucleic acid derived from each cell in the microbiota, enables absolute numerical evaluation of the microbiota composition cheaply and easily when performed before whole genome sequencing, and that after whole genome sequencing, narrowing down the information to be analyzed from the digital sequence information makes it possible to make comparisons using long gene sequences, thereby increasing accuracy, and have completed the present disclosure.
[0008] In one aspect, the present disclosure provides information on the digital counting of the absolute amount of the microbiome by comprehensively reading gene sequences that identify microbial species from amplified polynucleotides prepared in parallel on a cell-by-cell basis from a variety of microorganisms, and digitally counting the microbial species in a sample on a cell-by-cell basis. Examples of embodiments of the present disclosure include the following: (Item 1) A method for analyzing a microbiota composition, comprising: The method comprises a step of assessing the microbiota composition from a sample comprising amplified nucleic acid from each cell in the microbiota. (Item 1A) A method for analyzing a microbiome, comprising: A method comprising a step of evaluating the microbiome based on information from each nucleic acid derived from each cell in the microbiome. (Item 2) The amplified nucleic acid derived from each of the cells is Using a sample containing a microbiota, encapsulating cells one by one in a droplet; gelling the droplets to form gel capsules; immersing said gel capsule in one or more lysis reagents to lyse said cells, wherein a polynucleotide comprising said genomic DNA or a portion thereof is dissolved into said gel capsule and is retained within said gel capsule in a state where substances binding to said genomic DNA or a portion thereof have been removed; contacting the polynucleotide with an amplification reagent to amplify the polynucleotide within the gel capsule; 3. The method of any preceding claim, wherein the method is produced by a method comprising: (Item 3) A method according to any one of the above items, characterized in that the droplets encapsulating the cells are produced by flowing a suspension of the cells into a microchannel and shearing the suspension with oil. (Item 4) The method according to any of the preceding items, characterized in that the gel capsule is formed from agarose, acrylamide, PEG, gelatin, sodium alginate, Matrigel, collagen or a photocurable resin. (Item 5) The method according to any one of the preceding items, characterized in that the lysis reagent is at least one selected from the group consisting of lysozyme, labiase, yatalase, achromopeptidase, protease, nuclease, zymolyase, chitinase, lysostaphin, mutanolysin, sodium dodecyl sulfate, sodium lauryl sulfate, potassium hydroxide, sodium hydroxide, phenol, chloroform, guanidine hydrochloride, urea, 2-mercaptoethanol, dithiothreitol, TCEP-HCl, sodium cholate, sodium deoxycholate, Triton X-100, Triton X-114, NP-40, Brij-35, Brij-58, Tween 20, Tween 80, octylglucoside, octylthioglucoside, CHAPS, CHAPSO, dodecyl-β-D-maltoside, Nonidet P-40, and Zwittergent 3-12. (Item 6) The method according to any of the preceding items, characterized in that the gel capsule is a hydrogel capsule. (Item 7) The method according to any one of the preceding items, further comprising the step of selecting a sample containing the amplified nucleic acid to be analyzed from the samples containing the amplified nucleic acid derived from each of the cells. (Item 8) The method according to any one of the preceding items, comprising a step of detecting a nucleic acid having a specific sequence in a sample containing amplified nucleic acid derived from each of the cells. (Item 9) The method according to any of the preceding items, wherein the step of detecting a nucleic acid having a specific sequence comprises amplifying and sequencing the nucleic acid having a specific sequence. (Item 10) The method according to any of the preceding items, wherein the step of evaluating the microbiota composition includes determining the absolute number of each type of microorganism in the microbiota. (Item 11) The method according to any of the preceding items, further comprising a step of obtaining genomic sequence data for each of the cells in the microbiota from a sample containing amplified nucleic acid derived from each of the cells. (Item 12) The method according to any of the preceding items, further comprising a step of selecting genome sequence data to be analyzed from the genome sequence data of each of the cells. (Item 13) The method according to any of the preceding items, wherein the step of evaluating the microbiota composition includes comparing gene sequences (e.g., 16S rRNA gene sequences, 18S rRNA gene sequences, or sets of common genes) extracted from de novo assembly data for each microorganism. (Item 14) The method according to any of the preceding items, wherein the microbiota is a bacterial flora. (Item 15) The method according to any of the preceding items, wherein the microbiota is an intestinal microbiota. (Item 16) A kit for use in the method of any one of Items 1 to 15, comprising a specimen collection container containing a preservation solution. (Item 17) The kit described in Item 16, wherein the preservation solution contains guanidine or ethanol. (Item 18) A system for analyzing a microbiota composition, comprising: A sample providing unit that provides a sample containing amplified nucleic acid derived from each cell in the microbiota; a composition evaluation unit that evaluates the composition of the microbiota from a sample containing amplified nucleic acid derived from each cell in the microbiota; Including, the system. (Item 19) The sample providing unit is a droplet encapsulation unit that encapsulates cells one by one in droplets using a sample containing a microbiota; a gel capsule forming unit that gels the droplets to form gel capsules; a cell lysis unit that lyses the cells by immersing a gel capsule in one or more lysis reagents, the gel capsule storing one or more lysis reagents for lysing the cells, the cell lysis unit being configured such that a polynucleotide containing the genomic DNA of the cell or a portion thereof is dissolved in the gel capsule and a substance that binds to the genomic DNA or a portion thereof is removed and the polynucleotide is retained in the gel capsule; a polynucleotide amplification reagent for amplifying the polynucleotide in a gel capsule; 2. The system of claim 1, further comprising: (Item 20) The system of any of the preceding items, further comprising a specimen collection container containing a preservation fluid. (Item 21) The system described in any of the above items, further comprising a sample selection unit for selecting a sample containing amplified nucleic acid to be analyzed from samples containing amplified nucleic acid derived from each of the cells. (Item 22) The system described in any of the above items, wherein the composition evaluation unit includes a detection reagent or detection device for detecting a nucleic acid having a specific sequence in a sample containing amplified nucleic acid derived from each of the cells. (Item 23) The system described in claim 5A, wherein the detection reagent or detection device includes a nucleic acid amplification and sequencing device for amplifying and sequencing nucleic acid. (Item 24) The system described in any of the above items, wherein the composition evaluation unit includes a calculation unit that performs a procedure for identifying the absolute numbers of various microorganisms in the microbiome. (Item 25) The system described in any of the above items, wherein the composition evaluation unit further includes a genome sequence data acquisition unit that acquires genome sequence data of each of the cells in the microbiome from a sample containing amplified nucleic acid derived from each of the cells. (Item 26) The system described in any of the above items, wherein the composition evaluation unit further includes a data selection unit that selects genome sequence data to be analyzed from the genome sequence data of each of the cells. (Item 27) The system described in any of the above items, wherein the composition evaluation unit includes or introduces gene sequences extracted from de novo assembly data for each microorganism and has a function of comparing them.
[0009] It is contemplated that the present disclosure may provide one or more of the above features in combinations other than those specifically described. Still further embodiments and advantages of the present disclosure will be recognized by those skilled in the art upon reading and understanding the following detailed description, if necessary. Effect of the Invention
[0010] The present disclosure makes it possible to assess the microbiota based on information from each nucleic acid derived from every single cell in the microbiota, thereby enabling an absolute numerical assessment of the composition of the microbiota.
[0011] In the case of PCR-based microbiome analysis, a part of the amplified DNA sample can be used, and by performing PCR and then sequencing to determine the partial sequence, the microbiome composition can be evaluated from the information of a specific gene sequence, making it possible to perform a cheap and simple evaluation. When performing microbiome analysis based on digital sequence data, the digital sequence data obtained by sequencing can be used as the target, and the gene sequence to be used in the microbiome analysis can be extracted to create composition data, allowing for highly accurate analysis. This disclosure makes it possible to eliminate the problem of bias caused by the copy number and sequence of the target gene, while at the same time determining the absolute amount ratio rather than the relative composition ratio. Microorganisms with low composition ratios are sometimes grouped together as "others," but there is a concern that the microbial composition is estimated to be higher or lower than it actually is. The present disclosure enables more accurate measurement of the actual composition by enabling absolute number counting.
[0012] Therefore, the present disclosure has the effect of enabling cheap and easy evaluation of absolute numbers of microbiota composition when performed prior to whole genome sequencing, and by narrowing down the information to be analyzed from the digital sequence information after whole genome sequencing, it becomes possible to make comparisons using long gene sequences, thereby improving accuracy. [Brief description of the drawings]
[0013] [Figure 1] FIG. 1 shows a schematic diagram of the steps taken to prepare amplified DNA. [Diagram 2] FIG. 2 shows a schematic diagram of wet sequence screening. [Diagram 3] FIG. 3 is a schematic diagram of post-selection sequencing. [Figure 4] FIG. 4 is a schematic diagram showing the dry sequence screening steps. [Diagram 5] FIG. 5 is a schematic diagram showing the overall flow of microbiome analysis in the present disclosure. [Figure 6]Figure 6 shows box plots of genome sequencing rates (completion rates) of draft genomes created from amplified nucleic acids derived from single cells from fecal samples. The left graph shows the analysis results of single cells derived from fecal samples that were not immersed in a preservation solution, and the right graph shows the analysis results of single cells derived from fecal samples that were immersed in a preservation solution. [Figure 7] Figure 7 shows the results of bacterial evolutionary phylogenetic analysis from genome data of each sample, based on the draft genome created from amplified nucleic acid derived from a single cell from a fecal sample, and with reference to the marker gene group detected using CheckM. The left shows the analysis result of a single cell derived from a fecal sample that was not immersed in a preservation solution, and the right shows the analysis result of a single cell derived from a fecal sample that was immersed in a preservation solution. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0014] The present disclosure will be described below while showing the best mode. Throughout this specification, the expression of the singular form should be understood to include the concept of the plural form, unless otherwise specified. Therefore, the singular article (for example, in the case of English, "a", "an", "the", etc.) should be understood to include the concept of the plural form, unless otherwise specified. In addition, it should be understood that the terms used in this specification are used in the sense commonly used in the field, unless otherwise specified. Therefore, unless otherwise defined, all technical terms and scientific and technical terms used in this specification have the same meaning as commonly understood by those skilled in the art to which this disclosure belongs. In case of conflict, the present specification (including definitions) will take precedence.
[0015] The present disclosure relates to methods for microbe-specific detection and analysis of microbiomes (e.g., bacterial biota).
[0016] (Definition, etc.) The following provides definitions of terms particularly used in this specification and / or explains basic technical content as appropriate.
[0017] As used herein, a "cell" refers to any particle that contains molecules containing genetic information and is capable of replicating (whether independently or not). As used herein, a "cell" includes cells of unicellular organisms, bacteria, cells derived from multicellular organisms, fungi, viruses, and the like.
[0018] As used herein, a "biomolecule" refers to a molecule possessed by any organism or virus. Biological molecules may include nucleic acids, proteins, sugar chains, lipids, and the like. As used herein, a "biomolecule analog" refers to a natural or non-natural variant of a biomolecule. Biological molecule analogs may include modified nucleic acids, modified amino acids, modified lipids, modified sugar chains, and the like.
[0019] As used herein, a "population" refers to an assembly containing two or more single biological units, cells, or cell-like structures.
[0020] As used herein, a "subpopulation" refers to a portion of a population that has a smaller number of single biological units, cells, or cell-like structures than the population.
[0021] In this specification, "gel" refers to a state in which polymeric substances or colloidal particles in a colloidal solution (sol) form a network structure as a whole due to their interactions, and the solution loses fluidity while still containing a large amount of the liquid phase, which is the solvent or dispersion medium. In this specification, "gelation" refers to changing the solution into a "gel" state.
[0022] As used herein, the term "gel capsule" refers to a gel-like particulate structure capable of retaining cells or cell-like structures therein.
[0023] In this specification, "genetic analysis" refers to examining the state of nucleic acids (DNA, RNA, etc.) in a biological sample. In one embodiment, the genetic analysis may be one that utilizes a nucleic acid amplification reaction. Examples of genetic analysis, including the above, include sequencing, genotyping and polymorphism analysis (SNP analysis, copy number polymorphism, restriction fragment length polymorphism, repeat number polymorphism), expression analysis, fluorescence quenching probe (Quenching Probe: Q-Probe), SYBR green method, melting curve analysis, real-time PCR, quantitative RT-PCR, digital PCR, etc.
[0024] As used herein, the term "single-biological unit level" refers to processing the genetic information or other biomolecular information contained in one single biological unit in a state in which it can be distinguished from the genetic information or other biomolecular information contained in other single biological units.
[0025] As used herein, the term "single cell level" refers to processing the genetic information contained in one cell or cell-like structure in a state where it is distinguished from the genetic information contained in other cells or cell-like structures. For example, when amplifying polynucleotides at the "single cell level," amplification is performed in a state where the polynucleotides in a certain cell and the polynucleotides in other cells can be distinguished from each other.
[0026] As used herein, "single-cell analysis" refers to the analysis of genetic information contained in a single cell or cell-like structure while distinguishing it from genetic information contained in other cells or cell-like structures.
[0027] As used herein, "nucleic acid information" refers to information about the nucleic acids contained in a cell or cell-like structure, including the presence or absence of a particular gene sequence, the yield of a particular gene, or the total nucleic acid yield.
[0028] As used herein, "identity" refers to sequence similarity between two nucleic acid molecules. Identity can be determined by comparing positions in each sequence that can be aligned for comparison.
[0029] In this specification, the term "microbiota" refers to the entire collection of microorganisms present in a certain physical range. "Microorganisms" include organisms (or individual cells in the case of multicellular organisms) whose presence cannot be discerned by the naked eye and whose size is smaller than that which can be observed by a microscope or the like. Examples of a certain physical range include a certain range in the intestines, skin, oral cavity, nasal cavity, or vagina of an individual, or in water bodies, soil, the surface of an organism, or inside an organism in the environment. The microbiota may be a collection of microorganisms across multiple classifications, such as a combination of fungi, bacteria, archaea, unicellular animals, viruses, etc., or may be a collection of microorganisms from some classifications. One example of a microbiota is a bacterial flora.
[0030] As used herein, the "composition" of a microbiota refers to information about what species are contained in the microbiota or the amount of each species contained therein, and also includes information about the presence or amount of some microbial species in the microbiota.
[0031] (analysis) In one aspect of the present disclosure, a method for analyzing a microbiota is provided, comprising the step of evaluating the microbiota based on the information of each nucleic acid derived from each cell in the microbiota.Although the amount of nucleic acid of a certain sequence can be specified from the information of nucleic acid derived from a plurality of cells, the absolute amount of a specific type of microorganism cannot be measured because the copy number of each microorganism is different, but the absolute amount of a specific type of microorganism can be measured based on the information of nucleic acid derived from each cell.
[0032] In one embodiment of the present disclosure, a method for analyzing a microbiota composition may be provided, comprising a step of evaluating the microbiota composition from a sample containing amplified nucleic acid derived from each cell in the microbiota. Since the amount of nucleic acid derived from microorganisms per cell is small, it is common to use an amplification reaction even when analyzing nucleic acids derived from multiple cells in a mixed state. However, even when attempting to amplify nucleic acids as a whole, such as by using random primers, it is known that the degree of amplification for each sequence is biased due to GC content, etc. When amplification is biased, it is difficult to measure the relative amount of a specific species of microorganism in the microbiota.
[0033] (Single cell analysis) In the present disclosure, information on each nucleic acid derived from each cell may be obtained by any method, but in order to easily obtain information on each nucleic acid derived from each cell from a large number of cells, it may be preferable to obtain amplified nucleic acids from each cell by a method including the following steps: using a sample containing a microbiome, encapsulating cells one by one in a droplet; gelling the droplet to produce a gel capsule; and immersing the gel capsule in one or more types of lysis reagents to lyse the cells, wherein a polynucleotide containing the genomic DNA of the cell or a part thereof is dissolved into the gel capsule and retained in the gel capsule in a state in which substances binding to the genomic DNA or part thereof have been removed; and contacting the polynucleotide with an amplification reagent to amplify the polynucleotide in the gel capsule. In one embodiment of the present disclosure, the step of contacting the polynucleotide with an amplification reagent to amplify the polynucleotide within the gel capsule can also amplify the polynucleotide while maintaining the polynucleotide in a gel state within the gel capsule.
[0034] In one embodiment, the droplets can be created by flowing a single cell through a microchannel and encapsulating the single cell by shearing the suspension with oil. In some embodiments, the gel capsule can be a hydrogel capsule.
[0035] The material of the gel capsule may include agarose, acrylamide, photocurable resin (e.g., PEG-DA), PEG, gelatin, sodium alginate, Matrigel, collagen, etc. The gelation of the droplets can be achieved by forming the droplets so that they contain the material of the gel capsules and cooling the droplets. Alternatively, gelation can be achieved by applying a stimulus such as light to the droplets. The material of the gel capsules can be included in the droplets, for example, by including the material of the gel capsules in a suspension of cells or cell-like structures.
[0036] The gel capsule may be a hydrogel capsule. As used herein, "hydrogel" refers to a water solvent or dispersion medium held by a network of polymeric materials or colloidal particles.
[0037] The lysis reagent may be at least one selected from the group consisting of lysozyme, labiase, yatalase, achromopeptidase, protease, nuclease, zymolyase, chitinase, lysostaphin, mutanolysin, sodium dodecyl sulfate, sodium lauryl sulfate, potassium hydroxide, sodium hydroxide, phenol, chloroform, guanidine hydrochloride, urea, 2-mercaptoethanol, dithiothreitol, TCEP-HCl, sodium cholate, sodium deoxycholate, Triton X-100, Triton X-114, NP-40, Brij-35, Brij-58, Tween 20, Tween 80, octylglucoside, octylthioglucoside, CHAPS, CHAPSO, dodecyl-β-D-maltoside, Nonidet P-40, and Zwittergent 3-12.
[0038] When amplifying or analyzing nucleic acids on a cell-by-cell basis for various microorganisms, it is desirable to use a lysis reagent or combination of lysis reagents that are relatively strong, for example, Gram-positive bacteria have cell walls with a thick peptidoglycan layer, so that cells may not be sufficiently lysed with only a mild lysis reagent.
[0039] In the present disclosure, a method for preparing a sample containing amplified nucleic acid by dividing cells into individual cells includes a general method of separating single cells into tubes using a micromanipulator or flow cytometry, and adding a lysis reagent or a whole genome amplification reagent to each tube. Non-patent literature (Rinke C, Lee J, Nath N, et al. Obtaining genomes from uncultivated environmental microorganisms using FACS-based single-cell genomics. Nat Protoc.2014;9(5):1038-1048. doi:10.1038 / nprot.2014.067). As a method for evaluating the microbial composition, as reported in various literature such as non-patent literature (Vandeputte et al.2017 Nature), it is performed by sequencing a partial or entire sequence of the 16S rRNA gene.
[0040] The number of cells or cell-like structures that may be targeted in the microbiome analysis of the present disclosure may be any number of 2 or more, for example, 10 or more, 50 or more, 100 or more, 500 or more, 1000 or more, 5000 or more, 10,000 or more, 50,000 or more, 10,000 or more, 500,000 or more, 1 million or more, 5 million or more, 10 million or more. The microbiome analysis of the present disclosure may use information from each nucleic acid derived from each individual cell from a larger number of cells than using a conventional single-cell reaction system, for example, a 0.2 mL or 1.5 mL microtube reaction system. (Pre-genome sequencing analysis)
[0041] In the present disclosure, prior to performing an analysis of the entire sequence information of each microorganism (e.g., genome sequencing), individual-specific detection and selection may be performed from structures or sequences of nucleic acids or other biomolecules prepared in parallel from various microorganisms, with reference to the structures or sequences. That is, the method may include a step of selecting a sample containing amplified nucleic acid to be analyzed from samples containing amplified nucleic acid derived from each cell.
[0042] In one embodiment, selection can be based on the presence or absence of a specific gene sequence, the yield of a specific gene, or the total nucleic acid yield. In some embodiments, selection can be based on the presence or absence of a specific gene sequence. In some embodiments, selection can be based on the yield of a specific gene being higher or lower than a reference yield. In some embodiments, selection can be based on the total nucleic acid yield being higher or lower than a reference yield.
[0043] In certain embodiments, the presence or absence of a specific gene sequence is detected by a means selected from the group consisting of a reagent that specifically detects a specific gene sequence, agarose gel electrophoresis, microchip electrophoresis, PCR, qPCR, and gene sequencing (Sanger sequencing, NGS).In some embodiments, the reagent that specifically detects a specific gene sequence includes an antibody, a probe, a DNA-binding fluorescent dye, and a fluorescent dye-binding nucleotide.
[0044] In certain embodiments, specific gene yield or total nucleic acid yield can be measured by absorbance measurement, fluorometry, agarose gel electrophoresis, microchip electrophoresis.The method can include detecting nucleic acid having specific sequence in a sample containing amplified nucleic acid from each cell.Detecting nucleic acid having specific sequence can include amplifying and sequencing nucleic acid having specific sequence.
[0045] The evaluation of the microbiota composition can include determining the absolute number of each type of microorganism in the microbiota.The absolute number of each type of microorganism can be determined by identifying the microbial species for each amplified nucleic acid from each cell.The identification of the microbial species can be performed, for example, by identifying the presence or absence of a specific gene sequence.
[0046] (Analysis involving genome sequencing) The method of the present disclosure may include a step of obtaining genome sequence data of each cell in the microbiota from a sample containing amplified nucleic acid derived from the cell. By obtaining genome sequence data, it is possible to obtain information on the individual microorganisms in the microbiota not only as sequence information but also in terms of the function of the sequence.
[0047] It is possible to select genome sequence data to analyze from the genome sequence data of each cell. Genomic sequence data contains a large amount of information, so limiting the amount to be processed leads to reductions in labor and time.
[0048] The selection may include evaluating the presence or absence of a specific gene sequence and / or the identity with a specific gene sequence. In some embodiments, the identity with a specific gene sequence can be evaluated by using BLAST or the like. In certain embodiments, the selection may be based on the presence or absence of a specific gene sequence, and the nucleic acid information may be sorted for each cell. In other embodiments, the selection may be based on the identity between a specific gene sequence and nucleic acid information derived from two or more cells, and the nucleic acid information may be sorted for each cell. In some embodiments, the selection may be performed when the identity is equal to or greater than a certain level, or when the identity is equal to or less than a certain level. In certain embodiments, the identity may be 50% or more, 55% or more, 60% or more, 65% or more, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more, or 100%. In other embodiments, the identity may be 50% or less, 45% or less, 40% or less, 35% or less, 30% or less, 25% or less, 20% or less, 15% or less, 10% or less, 9% or less, 8% or less, 7% or less, 6% or less, 5% or less, 4% or less, 3% or less, 2% or less, 1% or less, or 0%.
[0049] When genome sequence data is available, the evaluation of the microbiota composition may be performed by comparing long gene sequences in each microorganism. The long sequence may be, for example, a gene sequence extracted from de novo assembly data (e.g., a 16S gene sequence or a set of common genes). Such a comparison of long gene sequences may not only increase the accuracy of the evaluation, but may also enable the evaluation of functions in the microbiota. For example, even if it is known that multiple species exist, the function of the entire microbiota cannot be understood without individual information on the function of each species based on sequence information alone. However, based on gene information, information can be obtained about the amount of species that may have a specific activity (e.g., enzyme activity) in the microbiota.
[0050] (microbiome) The microbiota that may be the subject of the present disclosure may include, but is not limited to, eubacteria, Escherichia coli, Bacillus subtilis, cyanobacteria, cocci, bacilli, spiral bacteria, gram-negative bacteria, gram-positive bacteria, archaea, fungi, or any combination thereof. An example of a microbiota is a bacterial flora. Since a microbiota may include a plurality of microorganisms having different cellular properties (e.g., the presence or absence of a cell wall, etc.), it may be preferable in the analysis of the present disclosure to employ a means that can obtain nucleic acid information for each cell or amplified nucleic acid for each cell in the same manner regardless of the microbial species.
[0051] The microbiota may be, but is not limited to, the intestinal microbiota, the skin microbiota, the oral microbiota, the nasal microbiota, the vaginal microbiota, the soil microbiota, the rhizosphere microbiota, the river / seawater microbiota, the activated sludge microbiota, the insect symbiotic microbiota, the animal symbiotic microbiota, etc. The intestinal microbiota has been widely studied for its influence on human health, and is one of the preferred subjects for analysis in the present disclosure.
[0052] (Combination embodiment) In the present disclosure, it is possible to perform analysis by further combining information from analyses of nucleic acid sequence information derived from the same microflora, but not from individual cells. An example of such analysis is metagenomic analysis. Metagenomic analysis is a method of extracting and collecting the nucleic acids, genes, and DNA of microorganisms in the environment as a whole, without going through the process of culturing, and comprehensively examining their structures (base sequences). Although it is not known which microorganism each individual nucleic acid or gene originates from, it is possible to obtain information about the gene group of a collection (community) of microorganisms in the environment, and this type of method is called metagenomic analysis.
[0053] (system) In another aspect of the present disclosure, a system for analyzing microbiota composition may be provided. The system may comprise means for implementing a method or steps thereof comprising any of the features described in other sections herein.
[0054] The system may include an apparatus for amplifying polynucleotides in cells. The apparatus may be capable of amplifying polynucleotides in cells at a single cell level, among others. The apparatus may include a droplet generator for encapsulating cells or cell-like structures in droplets one cell or structure at a time; a gel capsule generator for gelling the droplets to generate gel capsules; a lysis reagent immersion unit for immersing the gel capsules in a lysis reagent; a removal unit for removing contaminants from the gel capsules; and / or an amplification reagent immersion unit for immersing the gel capsules in an amplification reagent. The system or apparatus may further include a sorting unit for sorting the gel capsules and storing the gel capsules in a storage container.
[0055] The system or device may optionally include reagents such as a medium for encapsulating the cells or cell-like structures, a gel encapsulant, a lysis reagent, an amplification reagent, a reagent for sequencing the nucleic acid (e.g., a polymerase, a primer set (which may include a barcode sequence), etc.) Reagents may be used that are known in the art in addition to those described elsewhere herein.
[0056] The device or system may further include a sequencing unit for sequencing the nucleic acid sequence in the polynucleotide amplified in the amplification reagent immersion unit. The sequencing unit may be provided integrally with the device or as a separate device in the system. The sequencing unit may be an instrument for performing Sanger sequencing, Maxam-Gilbert sequencing, single molecule real-time sequencing (e.g., Pacific Biosciences, Menlo Park, California), ion semiconductor sequencing (e.g., Ion Torrent, South San Francisco, California), sequencing by synthesis, pyrosequencing (e.g., 454, Branford, Connecticut), sequencing by ligation (e.g., SOLiD sequencing, Life Technologies, Carlsbad, California), sequencing by synthesis and reversible terminator (e.g., Illumina, San Diego, California), nucleic acid imaging techniques such as transmission electron microscopy, nanopore sequencing, and the like.
[0057] The system or device may include a means for detecting and measuring the amplified genes. For example, a flow cytometry device suitable for handling the gel capsule shape may be provided integrally with the device or as a separate device in the system. The means for detecting and measuring the amplified genes may include a means for performing a detection reaction (e.g., a thermal cycler and appropriate reagents) and / or a means for detecting a signal (e.g., a light sensor, a camera, and appropriate analytical means).
[0058] The system or device may include a calculation unit that may be configured to perform any information processing described elsewhere herein. The calculation unit may be provided integrally with the device, or may be provided as a separate device (computer) in the system. In another aspect of the present disclosure, a program for performing the information processing described elsewhere herein in the calculation unit and implementing the method of the present disclosure and a storage medium having the program recorded thereon may also be provided. The calculation unit may include such a program and / or a storage medium having the program recorded thereon, as necessary.
[0059] (kit) One aspect of the present disclosure provides a kit that can be used in the method of the present disclosure. In the present disclosure, a kit for analyzing microbiota composition can be provided. The kit can include a gel capsule material, and the use of the gel capsule is advantageous for amplifying nucleic acid in a cell or cell-like structure at a single cell level as described elsewhere herein, and can be used as described herein for analyzing microbial composition. The kit can include, for example, a gel capsule material and, if necessary, one or more reagents. The reagents may be those known in the art in addition to those described elsewhere herein.
[0060] A kit for analyzing microbiota composition may include a lysis reagent. The lysis reagent may comprise at least one selected from the group consisting of lysozyme, labiase, yatalase, achromopeptidase, protease, nuclease, zymolyase, chitinase, lysostaphin, mutanolysin, sodium dodecyl sulfate, sodium lauryl sulfate, potassium hydroxide, sodium hydroxide, phenol, chloroform, guanidine hydrochloride, urea, 2-mercaptoethanol, dithiothreitol, TCEP-HCl, sodium cholate, sodium deoxycholate, Triton X-100, Triton X-114, NP-40, Brij-35, Brij-58, Tween 20, Tween 80, octyl glucoside, octyl thioglucoside, CHAPS, CHAPSO, dodecyl-β-D-maltoside, Nonidet P-40, Zwittergent 3-12. The lysis reagent is useful for obtaining amplified polynucleotides at the single cell level, particularly genome-wide amplification products.
[0061] The kit may include reagents for amplifying nucleic acids. Examples of the reagents for amplification include polymerase, a primer set (which may include a barcode sequence), a base mix, and a suitable buffer. The kit may include reagents used for sequencing nucleic acids (e.g., polymerase, a primer set (which may include a barcode sequence), and the like). For example, the kit may include reagents for amplifying and decoding specific genes in Sanger sequencing or NGS (polymerase, a primer set (which may include a barcode sequence), and others). The kit may also include reagents for detecting and measuring specific sequences, such as nucleic acid binding dyes and fluorescently labeled probes. Using these reagents, the presence or absence of specific sequences can be measured using an instrument (such as a flow cytometer) that detects and measures amplified genes.
[0062] The kit may include a means for collecting a sample. The kit may also include a means for storing the collected sample. Examples of means for collecting a sample include a syringe, a swab, a biopsy punch, a urine collection container, a stool collection container, a saliva collection container, and medical tape. Examples of means for storing the sample include a cooling agent (e.g., an ice pack, dry ice, liquid nitrogen) and a preservation solution (e.g., a solution containing any of guanidine hydrochloride, ammonium sulfate, ethanol, etc.).
[0063] In one aspect of the present disclosure, a kit for analyzing a microbiota composition may be provided, which includes a specimen collection container containing a preservation solution. The preservation solution may include, for example, a guanidine solution (e.g., FS-0007 or FS-0008, Techno Suruga Lab) or ethanol (e.g., OMR-200 or OM-501, DNA genotek). By using a kit containing such a preservation solution, even if the sample is stored at room temperature for a certain period of time in a hospital facility or the like, effects such as a good genome sequencing rate (completion rate) and identification of many biological lineages in the sample can be achieved in subsequent single-cell level analysis. In addition, the kit is much more convenient than the usual method of collecting and preserving stool as frozen stool.
[0064] A preservation solution is generally used to enhance the stability of nucleic acids. For example, a guanidine solution and alcohols are used to cause protein denaturation and inhibit the action of enzymes that promote the decomposition of nucleic acids. In the method of the present disclosure, it may be preferable to maintain the morphological stability of cells in the preservation of samples. This is because cells that are broken down are difficult to encapsulate in droplets, or because frequent occurrence of cell debris makes it difficult to obtain data. Therefore, it was expected that a preservation solution that causes protein denaturation would be disadvantageous to the stability of cell morphology, but in the examples of the present specification, it was unexpectedly found that many of the cells maintained their morphology well after storage in the preservation solution, and that this is particularly suitable for the method of the present disclosure.
[0065] (Preferred embodiment) A gel capsule containing amplified and retained polynucleotides derived from a single cell genome is prepared by a method including the steps of: encapsulating cells in droplets one cell or structure at a time; gelling the droplets to produce gel capsules; immersing the gel capsules in one or more lysis reagents to lyse the cells, in which the polynucleotides in the cells are dissolved in the gel capsules and retained in the gel capsules in a state in which substances that bind to the polynucleotides have been removed; and contacting the polynucleotides with an amplification reagent to amplify the polynucleotides in the gel capsules. The gel capsules are stained with a DNA-binding fluorescent dye or the like, and fluorescent-positive capsules are counted by flow cytometry. The number of fluorescent-positive capsules in a given volume corresponds to the total number of microorganisms introduced. In this case, the step of contacting the polynucleotides with an amplification reagent to amplify the polynucleotides in the gel capsules can also be performed while maintaining the polynucleotides in a gel state in the gel capsules.
[0066] Next, gel capsules that hold genomic DNA that has been amplified to a predetermined level are selected using a flow cytometer or the like, and the gel capsules are separated and collected on a microplate or the like for each cell. Furthermore, a whole genome amplification reaction is carried out in the plate using the polynucleotides in each gel capsule as a template, and this is used as a library master plate. Next, a portion of the reaction solution in the library master plate is taken out to prepare a replica plate. Using this replica as a template, amplification is carried out with a primer set specific to the target gene. Next, the sequence of the amplified product is identified by Sanger sequencing or the like, and the microbial species of each sample is identified.
[0067] More effectively, the above primer set contains a barcode sequence, and an amplification reaction is performed in which a different barcode is assigned to each sample, and the PCR products from multiple replica plates are pooled and next-generation sequencing is performed. After that, the plate / well number is identified by the barcode sequence, and the sequence of the PCR product is identified, thereby identifying the microbial species of hundreds to thousands of samples at once. The above primer set may be a mixture of primer sets targeting multiple gene regions. More specifically, the primer set is selected from primer sets targeting the v3-v4 and v1-v2 regions of the 16S rRNA gene, and primer sets for distinguishing bacteria, archaea, fungi, etc., such as 18S rRNA and ITS. If multiple types of the above primer sets are used simultaneously, bacteria, archaea, and fungi can be detected simultaneously.
[0068] Using one of the above methods, the microbial species contained in each gel capsule dispensed onto a well plate or similar device are identified and counted, and the number of microorganisms is added to the total number of microorganisms measured initially. In this reaction, all PCR reactions are performed separately, and the microbial species is identified and counted for each barcode, resulting in digital count data that reflects the number of cells. In other words, data that avoids bias due to differences in copy number and sequence, which was a conventional problem, is obtained. In addition, it is possible to compare the actual total number of rare cells with a relative ratio of 1% or less.
[0069] (system) A gel capsule containing an amplified and retained single-cell genome-derived polynucleotide is prepared by a system for analyzing the composition of a microbiome, the system comprising a cell lysis unit comprising a droplet encapsulation unit which encapsulates cells one by one in a droplet, a gel capsule generation unit which gels the droplet to generate a gel capsule, and a cell lysis unit which stores one or more lysis reagents for lysing the cells and immerses the gel capsule in the one or more lysis reagents, the cell lysis unit being configured so that a polynucleotide containing the genomic DNA of the cell or a part thereof is dissolved into the gel capsule and is retained in the gel capsule in a state in which substances binding to the genomic DNA or part thereof have been removed, and a polynucleotide amplification reagent for amplifying the polynucleotide within the gel capsule.
[0070] Using the gel capsules prepared in this way, it is possible to perform a composite analysis of the genetic information of the host itself, such as humans, and the microbiota of a human-derived sample. For example, the microbial species contained in the sample is identified from each gel capsule obtained by the above-mentioned method and system for the human intestinal microbiota, and the information on the intestinal microbiota is analyzed together with the genetic information obtained from each gel capsule obtained by the above-mentioned method and system for human cells. In this case, the composition evaluation unit of the above-mentioned system can evaluate the human intestinal microbiota and human cells that are the subject of evaluation, respectively, to amplify and sequence the nucleic acid, and obtain the genome sequence data of each cell. In this way, the system of the present invention can evaluate the effects of intestinal bacteria and metabolites derived from them on the host, as well as the function of the intestinal bacteria themselves, and can find correlations between them.
[0071] All references cited herein, including scientific literature, patents, patent applications, and the like, are hereby incorporated by reference in their entirety to the same extent as if each was specifically set forth.
[0072] The present disclosure has been described above by showing preferred embodiments for ease of understanding. The present disclosure will be described below based on examples, but the above description and the following examples are provided for illustrative purposes only and are not provided for the purpose of limiting the present disclosure. Therefore, the scope of the present disclosure is not limited to the embodiments or examples specifically described in this specification, but is limited only by the scope of the claims. EXAMPLES
[0073] Examples of the present disclosure are described below. The specific reagents used were those described in the Examples, but equivalent products from other manufacturers (Sigma-Aldrich, Wako Pure Chemical Industries, Nakarai, R&D Systems, USCN Life Science INC, etc.) can also be used.
[0074] (Example 1: Analysis of mouse intestinal microbiota composition) For the experiment, feces from male BALB / c mice (7 and 9 weeks old) (CLEA Japan, Inc.) were collected in 1.5 mL tubes (1212-10, SSIbio) (n=5) and crushed in 500 μL of phosphate-buffered saline (DPBS) (Dulbecco's Phosphate-Buffered Saline, 14190-144, Thermo Fisher Scientific) using a grinder until no solid matter remained. The mouse intestinal microorganisms were collected by centrifuging at 2,000 × g for 2 seconds (himac CF15RX, Koki Holdings) and collecting the supernatant twice, followed by centrifugation at 15,000 × g for 3 minutes. The bacterial pellet was washed twice with PBS by centrifugation, and then suspended in PBS to obtain a cell suspension of mouse intestinal microorganisms. The cell concentration in the prepared cell suspension was measured (microscope: CKX41, OLYMPUS, bacterial counting chamber A161, 2-5679-01, AS ONE), and ultra-low melting point agarose (A5030-10G, SIGMA-ALDRICH) was added to a final concentration of 1.5% to prepare the intestinal microbial suspension to be used for producing gel capsules (final cell concentration: 1.5 × 10 3 cells / μL).
[0075] Using a microchannel made by ourselves using polydimethylsiloxane (Sylgard 184: Dow Corning), we prepared microdroplets and encapsulated mouse intestinal microbial cells in the microdroplets. In this example, we used a microchannel consisting of a first channel, a second channel, a third channel, and a fourth channel, with adjacent channels arranged at right angles, but it is also possible to use a microchannel connected in an approximately T-shape. In this example, we used a microchannel with a width of 34 μm and a height of 50 μm, but the size of the microchannel can be changed appropriately depending on the size of the microdroplets to be prepared and the size of a single cell to be encapsulated.
[0076] Next, an intestinal microorganism suspension was introduced from the first flow path (aqueous phase inlet), and Pico-Surf1 (2% in Novec7500) (Sphere Fluidics) (hereinafter referred to as "oil") was introduced from the second and fourth flow paths (oil phase inlets) to shear the intestinal microorganism suspension, producing microdroplets with a diameter of 50 μm, which were then flowed through the third flow path 7 and collected in a tube with a capacity of 0.2 mL. Approximately 450,000 microdroplets were produced at a rate of 500 droplets / second. The cell concentration in the microdroplets was 0.1 cells / droplet.
[0077] In this embodiment, the diameter of the microdroplets is uniformly set to 50 μm, so that cells are easily encapsulated in the microdroplets one by one. Considering the size of a single cell, the diameter of the microdroplets is, for example, 1 to 250 μm, and preferably 20 to 200 μm. The diameter of the droplets may be about 1 to 250 μm, more preferably about 10 to 200 μm, and for example, the diameter of the droplets may be about 1 μm, about 5 μm, about 10 μm, about 15 μm, about 20 μm, about 25 μm, about 30 μm, about 40 μm, about 50 μm, about 80 μm, about 100 μm, about 150 μm, about 200 μm, or about 250 μm.
[0078] A number of microdroplets and oil are contained in the tube, and since the microdroplets have a lower specific gravity than the oil, they accumulate in the upper layer.
[0079] Next, the tube was cooled on ice for 15 minutes, and the microdroplets were gelled with ultra-low melting point agarose. The gelled microdroplets are gel capsules. Since the diameter of the microdroplets is 50 μm, the diameter of the gel capsule is also 50 μm. The diameter of the gel capsule may be about 1 to 250 μm, more preferably about 10 to 200 μm, for example, about 1 μm, about 5 μm, about 10 μm, about 15 μm, about 20 μm, about 25 μm, about 30 μm, about 40 μm, about 50 μm, about 80 μm, about 100 μm, about 150 μm, about 200 μm, or about 250 μm. The diameter of the gel capsule may be the same as that of the droplets to be prepared, but the diameter may change during gelling. In addition, the diameter of the gel capsule is preferably 1 to 250 μm. By making the diameter of the gel capsules uniform, the rate of penetration of the lysis reagent, which will be described later, into each gel capsule can be made more uniform.
[0080] Next, 20 μL of 1H,1H,2H,2H-perfluoro-1-octanol (SIGMA-ALDRICH) was added to the tube, and the oil in the lower layer was removed. Then, acetone (FUJIFILM Wako Pure Chemical Industries, Ltd.) (500 μL) and isopropanol (FUJIFILM Wako Pure Chemical Industries, Ltd.) (500 μL) were added in that order, and the tube was centrifuged to remove the oil. The centrifugal washing to remove the oil was performed by the removal unit described below. In this example, the oil that has permeated the gel capsules is also included in the impurities. Furthermore, 500 μL of PBS was added, and centrifugal washing was performed three times, leaving the gel capsules suspended in the aqueous layer (PBS). The gel capsules accumulated in the lower layer because they have a higher specific gravity than the aqueous layer.
[0081] Next, the gel capsules were successively immersed in a bacteriolysis reagent as a lysis reagent, and inside the gel capsules, parts of the cells other than the collected target material, such as cell walls, were dissolved, and genomic DNA was eluted into the gel capsules.
[0082] Specifically, lysozyme (10 U / μL) (R1804M, Epicentre), a type of lysis reagent, was added to the tube to lyse the cells. Next, achromopeptidase (850 U / mL) (015-09951, Fujifilm Wako Pure Chemical) was added to the tube, a type of lysis reagent. Next, protease K (1 mg / mL) (MC5005, Promega) and sodium dodecyl sulfate (SDS) 0.5% (71736-100ML, SIGMA-ALDRICH), a type of lysis reagent, were added to the tube to lyse the cells, and then centrifugal washing was performed five times to remove components (contaminants) other than the protease and the genomic DNA of the lysed cells from the tube. Next, the gel capsule was immersed in Buffer D2 (QIAGEN), an aqueous solution containing potassium hydroxide, a type of lysis reagent, to dissolve the remaining components and denature the genomic DNA. The lysis reagent used in this example was lysozyme, achromopeptidase, protease K, sodium dodecyl sulfate, and Buffer D2, as described above. Potassium hydroxide is also used in the normal DNA amplification reaction process, but since it also has a lysis effect, it was used as one of the lysis reagents in this example. Since the gel capsule is immersed in the lysis reagent for a short time, the eluted genomic DNA is not shed outside the gel capsule by the lysis reagent, but is retained within the gel capsule. In this example, the lysis reagent that has permeated the gel capsule is also included in the impurities.
[0083] In this example, lysozyme, achromopeptidase, and protease K were added in sequence, sodium dodecyl sulfate was added to lyse the cells, and then centrifugation washing was performed only before adding Buffer D2. This allows for a sufficient washing effect. However, centrifugation washing may also be performed after the cells are lysed with each lysis reagent.
[0084] In this way, the target genomic DNA can be collected by lysing the cells using multiple types of lysis reagents, and by immersing the cells in the lysis reagents and then centrifugal washing, contaminants such as components other than the polynucleotides of the lysis reagents and the lysed cells can be removed, allowing the genomic DNA to be purified without inhibiting the subsequent genomic DNA amplification reaction.
[0085] Amplification reagent was added to a tube containing a gel capsule that holds genomic DNA denatured in potassium hydroxide solution (Buffer D2), and the gel capsule was immersed in the amplification reagent. Specifically, the MDA (Multiple Displacement Amplification) method using phi29 DNA polymerase, a strand-displacement DNA polymerase, was used. Here, the gel capsule was immersed in the whole genome amplification reaction reagent REPLI-g Single Cell Kit (QIAGEN), and the whole genome amplification reaction was carried out for 3 hours (S1000 Thermal Cycler, Bio-Rad). The amplification reagent (REPLI-g Single Cell Kit) contains a component that neutralizes the potassium hydroxide solution (Buffer D2).
[0086] In addition, the gel capsules were stained with a fluorescent DNA intercalator (SYBR Green I nucleic acid gel stain 10,000 in DMSO, (S7563, Thermo Fisher Scientific)), and fluorescent gel capsules were individually collected from each fecal sample (n=5) in groups of 94 onto a plate (PCR-96-FS-C, Axygen) using a flow cytometer (BD FACSMelody cell sorter, BD Biosciences) (470 in total).
[0087] The collected gel capsules were each dissolved by heating at 65°C (S1000 Thermal Cycler, Bio-Rad), and secondary amplification was then performed in the wells of each plate using the MDA method (REPLI-g Single Cell Kit, 150345, QIAGEN) to create a library master plate containing 10 μL of DNA amplified product per well.
[0088] 39 μL of nuclease-free water (UltraPure DNase / RNase-Free Distilled Water, 10977-015, Thermo Fisher Scientific) was dispensed into each well of a new plate, and 1 μL of the DNA amplified product in the library master plate was added to prepare a 40-fold dilution of the library master plate. Next, DNA concentration was quantified using a Qubit fluorometer (Q33226, Thermo Fisher Scientific) and Qubit dsDNA HS Assay Kit (Q32854, Thermo Fisher Scientific) using 1 μL of the diluted solution. In addition, PCR targeting the V3V4 region of the 16S rRNA gene was performed using 1 μL of the diluted solution as a template (6.25 μL PrimeSTAR Max DNA Polymerase (R045B, Takara Bio), 0.5 μL 10 μM Primer Forward (5'-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCWGCAG-3' (SEQ ID NO: 1)), 0.5 μL 10 μM Primer Reverse (5'-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACTACHVGGGTATCTAATCC-3' (SEQ ID NO: 2)), 1.0 μL DNA diluted solution, 4.25 μL UltraPure DNase / RNase-Free Distilled Water (10977-015, Thermo Fisher Scientific) (S1000 Thermal Cycler, Bio-Rad). The PCR reaction conditions were initial heat denaturation at 95°C, The DNA was incubated at 98°C for 5 minutes, denatured at 98°C for 10 seconds, annealed at 51°C for 15 seconds, and extended at 72°C for 5 seconds for 27 cycles. After incubation at 72°C for 5 minutes, the DNA was stored at 4°C. Agarose gel electrophoresis (electrophoresis tank: Mupid-exU, EXU-1, Mupid, marker: GeneRuler TMThe presence or absence of PCR products was confirmed using 1 kb DNA Ladder, #SM0318, Fermentas, staining: Midori Green Direct, NE-MG06, Nippon Genetics, loading buffer: 6x Loading Buffer, 9157, Takara Bio) (electrophoresis conditions: 100 V, 15 min), and samples in which amplification was observed were subjected to sequence analysis using the Sanger method (DNA sequencing outsourcing service of FASMAC Corporation).
[0089] (Selection criteria) In this example, of the 470 samples amplified by MDA, the following criteria were set: (1) the DNA yield after MDA amplification is 200 ng or more; (2) amplification is confirmed after PCR of the 16S rRNA gene. Samples that meet the criteria that the DNA yield is sufficient for subsequent analysis and that they are of bacterial origin were selected. As a result of sample selection, 347 out of 470 samples (74%) were selected. Furthermore, a homology search (default conditions) using BLAST was performed on the sequence information obtained by sequence analysis of the PCR products to obtain information on the type and number of bacteria contained in the library master plate. In this example, the results of the homology search using BLAST confirmed many single-cell amplified genomic libraries classified into Lachnospiraceae and Bacteroidaceae, with 147 being Lachnospiraceae bacteria and 68 being Bacteroidaceae bacteria (table below). [Table 1]
[0090] (Example 2: Analysis of human intestinal microbiota composition) (Sample collection from humans) Human feces were collected in a collection container (FS-0007 or FS-0008, Techno Suruga Lab). For collection containers containing preservative solution, the preservative solution was removed after centrifugation at 8000xg for 5 min at 4°C, and the samples were washed once with 1000 μL of DPBS. Frozen feces (in 1.5 ml tubes) were left on ice for 30 minutes to thaw naturally. Fresh feces without preservative solution did not require any special treatment before crushing. The samples were then crushed in 500 μL of phosphate-buffered saline (DPBS) (Dulbecco's Phosphate-Buffered Saline, 14190-144, Thermo Fisher Scientific) using a crusher until no solid matter remained. The mouse intestinal microorganisms were collected by centrifugation at 2,000 × g for 2 seconds (himac CF15RX, Koki Holdings) and the supernatant was collected twice, followed by centrifugation at 15,000 × g for 3 minutes. The bacterial pellet was washed twice with PBS by centrifugation and then suspended in PBS to obtain a cell suspension of mouse intestinal microorganisms. The cell concentration in the prepared cell suspension was measured (microscope: CKX41, OLYMPUS, bacterial counting chamber A161, 2-5679-01, AS ONE), and ultra-low melting point agarose (A5030-10G, SIGMA-ALDRICH) was added to a final concentration of 1.5% to prepare the intestinal microorganism suspension to be used for gel capsule production (final cell concentration: 1.5 × 10 3 cells / μL).
[0091] (Processing of collected samples (wet)) Using a microchannel made by ourselves using polydimethylsiloxane (Sylgard 184: Dow Corning), we produced microdroplets and encapsulated human intestinal microbial cells in the microdroplets. In this example, we used a microchannel consisting of a first channel, a second channel, a third channel, and a fourth channel, with adjacent channels arranged at right angles, but it is also possible to use a microchannel connected in an approximately T-shape. In this example, we used a microchannel with a width of 34 μm and a height of 50 μm, but the size of the microchannel can be changed appropriately depending on the size of the microdroplets to be produced and the size of a single cell to be encapsulated.
[0092] Next, an intestinal microorganism suspension was introduced from the first flow path (aqueous phase inlet), and Pico-Surf1 (2% in Novec7500) (Sphere Fluidics) (hereinafter referred to as "oil") was introduced from the second and fourth flow paths (oil phase inlets) to shear the intestinal microorganism suspension, producing microdroplets with a diameter of 50 μm, which were then flowed through the third flow path 7 and collected in a tube with a capacity of 0.2 mL. Approximately 450,000 microdroplets were produced at a rate of 500 droplets / second. The cell concentration in the microdroplets was 0.1 cells / droplet.
[0093] In this embodiment, the diameter of the microdroplets is uniformly set to 50 μm, which makes it easier to encapsulate individual cells in the microdroplets. Considering the size of a single cell, the diameter of the microdroplets is, for example, 1 to 250 μm, and preferably 10 to 200 μm.
[0094] A number of microdroplets and oil are contained in the tube, and since the microdroplets have a lower specific gravity than the oil, they accumulate in the upper layer.
[0095] Next, the tube was cooled on ice for 15 minutes, and the microdroplets were gelled with ultra-low melting point agarose. The gelled microdroplets were gel capsules. Since the diameter of the microdroplets was 50 μm, the diameter of the gel capsules was also 50 μm. The diameter of the gel capsules is preferably 1 to 250 μm. By making the diameter of the gel capsules uniform, the penetration rate of the lysis reagent into each gel capsule, which will be described later, can be made more uniform.
[0096] Next, 20 μL of 1H,1H,2H,2H-perfluoro-1-octanol (SIGMA-ALDRICH) was added to the tube, and the oil in the lower layer was removed. Then, acetone (FUJIFILM Wako Pure Chemical Industries, Ltd.) (500 μL) and isopropanol (FUJIFILM Wako Pure Chemical Industries, Ltd.) (500 μL) were added in that order, and the tube was centrifuged to remove the oil. The centrifugal washing to remove the oil was performed by the removal unit described below. In this example, the oil that has permeated the gel capsules is also included in the impurities. Furthermore, 500 μL of PBS was added, and centrifugal washing was performed three times, leaving the gel capsules suspended in the aqueous layer (PBS). The gel capsules accumulated in the lower layer because they have a higher specific gravity than the aqueous layer.
[0097] Next, the gel capsules were successively immersed in a bacteriolysis reagent as a lysis reagent, and inside the gel capsules, parts of the cells other than the collected target material, such as cell walls, were dissolved, and genomic DNA was eluted into the gel capsules.
[0098] Specifically, lysozyme (10 U / μL) (R1804M, Epicentre), a type of lysis reagent, was added to the tube to lyse the cells. Next, achromopeptidase (850 U / mL) (015-09951, Fujifilm Wako Pure Chemical) was added to the tube, a type of lysis reagent. Next, protease K (1 mg / mL) (MC5005, Promega) and sodium dodecyl sulfate (SDS) 0.5% (71736-100ML, SIGMA-ALDRICH), a type of lysis reagent, were added to the tube to lyse the cells, and then centrifugal washing was performed five times to remove components (contaminants) other than the protease and the genomic DNA of the lysed cells from the tube. Next, the gel capsule was immersed in Buffer D2 (QIAGEN), an aqueous solution containing potassium hydroxide, a type of lysis reagent, to dissolve the remaining components and denature the genomic DNA. The lysis reagent used in this example was lysozyme, achromopeptidase, protease K, sodium dodecyl sulfate, and Buffer D2, as described above. Potassium hydroxide is also used in the normal DNA amplification reaction process, but since it also has a lysis effect, it was used as one of the lysis reagents in this example. Since the gel capsule is immersed in the lysis reagent for a short time, the eluted genomic DNA is not shed outside the gel capsule by the lysis reagent, but is retained within the gel capsule. In this example, the lysis reagent that has permeated the gel capsule is also included in the impurities.
[0099] In this embodiment, sufficient washing effect can be obtained by sequentially adding lysozyme, achromopeptidase, and protease K, adding sodium dodecyl sulfate to lyse the cells, and then performing centrifugation washing only before adding Buffer D2. However, centrifugation washing may be performed after the cells are lysed with each lysis reagent.
[0100] In this way, the target genomic DNA can be collected by lysing the cells using multiple types of lysis reagents, and by immersing the cells in the lysis reagents and then centrifugal washing, contaminants such as components other than the polynucleotides of the lysis reagents and the lysed cells can be removed, allowing the genomic DNA to be purified without inhibiting the subsequent genomic DNA amplification reaction.
[0101] Amplification reagent was added to a tube containing a gel capsule that holds genomic DNA denatured in potassium hydroxide solution (Buffer D2), and the gel capsule was immersed in the amplification reagent. Specifically, the MDA (Multiple Displacement Amplification) method using phi29 DNA polymerase, a strand-displacement DNA polymerase, was used. Here, the gel capsule was immersed in the whole genome amplification reaction reagent REPLI-g Single Cell Kit (QIAGEN), and the whole genome amplification reaction was carried out for 3 hours (S1000 Thermal Cycler, Bio-Rad). The amplification reagent (REPLI-g Single Cell Kit) contains a component that neutralizes the potassium hydroxide solution (Buffer D2).
[0102] In addition, the samples were stained with a fluorescent DNA intercalator (SYBR Green I nucleic acid gel stain 10,000 in DMSO, (S7563, Thermo Fisher Scientific)), and fluorescent gel capsules were individually collected from each fecal sample (n=2) in groups of 94 onto a plate (PCR-96-FS-C, Axygen) using a flow cytometer (BD FACSMelody cell sorter, BD Biosciences) (total of 188 gel capsules).
[0103] The collected gel capsules were each dissolved by heating at 65°C (S1000 Thermal Cycler, Bio-Rad), and secondary amplification was then performed in the wells of each plate using the MDA method (REPLI-g Single Cell Kit, 150345, QIAGEN) to create a library master plate containing 10 μL of DNA amplified product per well.
[0104] 39 μL of nuclease-free water (UltraPure DNase / RNase-Free Distilled Water, 10977-015, Thermo Fisher Scientific) was dispensed into each well of a new plate, and 1 μL of the DNA amplified product in the library master plate was added to prepare a 40-fold dilution of the library master plate. Next, DNA concentration was quantified using a Qubit fluorometer (Q33226, Thermo Fisher Scientific) and Qubit dsDNA HS Assay Kit (Q32854, Thermo Fisher Scientific) using 1 μL of the diluted solution. In addition, PCR was performed targeting the V3V4 region of the 16S rRNA gene using 1 μL of the diluted solution as a template (6.25 μL PrimeSTAR Max DNA Polymerase (R045B, Takara Bio), 0.5 μL 10 μM Primer Forward (5'-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCWGCAG-3' (Sequence No. 1)), 0.5 μL 10 μM Primer Reverse (5'-GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACTACHVGGGTATCTAATCC-3' (Sequence No. 2)), 1.0 μL DNA diluted solution, 4.25 μL UltraPure DNase / RNase-Free Distilled Water (10977-015, Thermo Fisher Scientific) (S1000 Thermal Cycler, Bio-Rad). The PCR reaction conditions were initial heat denaturation at 95°C, The DNA was incubated at 98°C for 5 minutes, denatured at 98°C for 10 seconds, annealed at 51°C for 15 seconds, and extended at 72°C for 5 seconds for 27 cycles. After incubation at 72°C for 5 minutes, the DNA was stored at 4°C. Agarose gel electrophoresis (electrophoresis tank: Mupid-exU, EXU-1, Mupid, marker: GeneRuler TMThe presence or absence of PCR products was confirmed using 1 kb DNA Ladder, #SM0318, Fermentas, staining: Midori Green Direct, NE-MG06, Nippon Genetics, loading buffer: 6× Loading Buffer, 9157, Takara Bio) (electrophoresis conditions: 100 V, 15 min), and samples in which amplification was observed were subjected to sequence analysis using the Sanger method (DNA sequencing outsourcing service of FASMAC Corporation).
[0105] (Analysis of data obtained at the single cell level) (Selection criteria) In this example, 96 of the 188 samples amplified by MDA were selected, and the following criteria were set: (1) the DNA yield after MDA amplification is 200 ng or more; (2) amplification is confirmed after PCR of the 16S rRNA gene. Samples that have sufficient DNA yield for subsequent analysis and meet the criteria of being of bacterial origin were selected. As a result of sample selection, 95 samples were selected. In addition, a homology search (default conditions) was performed using BLAST on the sequence information obtained by sequence analysis of the PCR products to obtain information on the type and number of bacteria contained in the library master plate.
[0106] For the 95 samples, libraries were prepared using the Nextera XT DNA sample prep kit (Illumina, FC-131-1096), and 2 × 75 bp paired-end reads were obtained by whole-genome sequencing using Miseq (Illumina, SY-410-1003). Sequencing data were assembled using SPAdes (Bankevich A et al., J Comput Biol. 2012 May;19(5):455-77. http: / / doi.org / 10.1089 / cmb.2012.0021) to generate contigs. In addition, the genome sequencing rate (completion rate) and the degree of contamination were evaluated using CheckM (Parks et al., Genome Res. 2015. 25: 1043-1055, doi:10.1101 / gr.186072.114) under default conditions. As a result, the average completion rate was 37.8% and the average contamination rate was 1.3% for fresh stool samples, and the average completion rate was 52.6% and the average contamination rate was 4.8% for preserved liquid stool samples (Figure 6).
[0107] Furthermore, the marker genes detected using CheckM were used to perform evolutionary phylogenetic analysis of bacteria from the genome data of each sample. As a result, it was shown that most of the data were derived from the phyla Firmicutes, Actinobacteria, Bacteroidetes, and Proteobacteria, which are predominant species of enterobacteria. By referring to such phylogenetic indicators and the identity of the 16SrRNA gene, it is possible to identify and count bacterial species and calculate the composition ratio as shown in Figure 7. In addition, by analyzing the digital sequence information of the bacteria, it is possible to analyze the metabolic function of the bacteria, whether they possess drug resistance genes, analyze gene mutations, compare them with known bacteria, and compare them with other samples. This process can be performed using, for example, search engines such as blast, analysis websites such as Ensembl, assembly evaluation tools such as QUAST and CheckM, annotation tools such as Prokka, InterProScan, and DFAST, and metabolic and physiological function potential evaluation systems such as MetaCyc and MAPLE. The process of analyzing genetic information involves using QUAST to evaluate the effectiveness of the assembly obtained by denovo assembly, and CheckM to evaluate the quality of the genome set. After that, annotation tools such as Prokka are used to identify genes in the genome, and MAPLE is used to evaluate their conservation as metabolic pathways. The conservation and identity of each gene is evaluated using the Pfam and COG databases, and comparative genome analysis with closely related organisms is performed.
[0108] More specifically, when the purpose is to evaluate gene mutations on a single-cell basis, (1) a homology search of gene sequences from a single organism using BLAST or hmmer is performed on the target gene, or (2) a mapping of sequence data from a single organism using BWA or bowtie2 is performed to detect differences between the gene sequence from a single organism and the target gene sequence, thereby identifying gene mutations.
[0109] For the purpose of comparison with known bacteria, comparison with other samples, and subspecies analysis, a genome set is created that includes gene information from a single organism presumed to be from the same species of microorganism and gene information from known microorganisms based on the average nucleotide identity and single copy marker gene sequences detected by CheckM and GTDB-tk. Then, differences between genomes, such as the presence or absence of specific genes, gene loci, and mutations in common gene sequences, are identified and extracted using homology search tools such as BLAST and hmmer. Clustering based on characteristic genome differences is performed to classify the same species of microorganisms at the strain level or the same strain of microorganisms at the substrain level.
[0110] (Example 3: When you want to selectively obtain data on cells with specific characteristics from among a variety of cells) When the purpose is to obtain genome data of one or more specific microorganisms that are of interest to a person skilled in the art among animal symbiotic microorganisms such as enterobacteria or marine and soil microorganisms, the presence or absence of gene fragments of the target microorganism in advance in gel capsules containing polynucleotides or amplified nucleic acids recovered from the gel capsules can be confirmed in advance to reduce the acquisition of unnecessary gene sequence data and the associated costs. Examples of measurement targets include comparative analysis of microorganisms of the same lineage (e.g., analysis of subspecies in a microbial lineage related to a disease, etc.), searching for microorganisms having specific genes (e.g., secondary metabolites or enzymes produced by microorganisms), or individually selecting and analyzing bacteria, archaea, fungi, and other eukaryotic cells from among organisms of multiple lineages. In particular, it is expected to specifically detect enterobacteria and oral bacteria that have specific metabolic functions from genes, or to detect subspecies of skin bacteria, for the purpose of evaluating the intestinal environment, oral cavity, and skin environment of the host human.
[0111] (Example 4: When a large amount of host DNA, etc. is present) When the analysis sample is feces, saliva, sputum, swabs from the skin, oral cavity, nasal cavity, ears, genitals, etc., surgical washings, or tissue extracts or blood, and the microorganisms contained in the sample are the subject of analysis, the sample contains many cells, intracellular organelles, and nucleic acids derived from the host animal. Some of these may also be encapsulated inside the gel capsule to perform polynucleotide amplification. For this reason, by confirming in advance the presence or absence of gene fragments of the target microorganism or gene fragments derived from the host in the gel capsule containing the amplified polynucleotide, it is possible to avoid obtaining unnecessary gene sequence data including polynucleotides derived from the host, and to reduce the costs involved. Examples of measurements include the detection of microorganisms from human samples, such as the search for pathogenic microorganisms from blood or sputum, and the analysis of microorganisms coexisting inside tissues.
[0112] Alternatively, by actively analyzing host-derived polynucleotides, this method can be applied to the comprehensive analysis of the microbiota.
[0113] For example, it is known that the intestinal flora in the digestive tract and the host animal have a symbiotic relationship in which the host provides an anaerobic environment for the colonization of the gut flora, while the intestinal flora influences the health of the host. For example, the major influences on the host's health include the production of nutrients and the development of the immune system and defense against infectious diseases. Another example is inflammatory bowel disease, which is a disease caused by a combination of genetic predisposition and abnormalities in intestinal environmental factors, including intestinal bacteria.
[0114] For such pathologies, it is necessary to analyze the genetic information of the host itself, to perform an integrated analysis of the intestinal microbiota, i.e., bacteria, viruses, and fungi, and to clarify the mechanism of action on the host's physiological functions, and the technology disclosed herein can contribute to these. In addition, the relationship between the intestinal microbiota and the pathologies of various diseases and functional analysis centered on metabolic products can be further analyzed by analyzing the genetic information of the host itself.
[0115] In addition, in the intestinal tract, while the intestinal bacteria compete with the host for nutrients, the intestinal bacteria also metabolize and break down nutrients for the host, allowing for more integrated analysis. In this way, the functions of metabolites derived from intestinal bacteria can be analyzed in a comprehensive manner, including genetic analysis, metabolome analysis, and biochemical analysis of the host, and the functions of intestinal bacteria can be inferred from the bacterial genome sequence information and a correlation can be seen with the metabolites produced.
[0116] Example 5: Evaluation of gene mutations in single cells It is possible to evaluate the mutation diversity in genome sequences at the single-cell level, and to track the genomic heterogeneity of each microorganism in the microbiome and the occurrence and progress of mutation lineages. By selectively amplifying and detecting the target gene mutation site of the target cell in the gel capsule containing the amplified polynucleotide, it is possible to specifically obtain only the gene sequence data to be analyzed, reducing the cost involved. It can be used to detect genetically mutated microorganisms and plasmid infections.
[0117] (Example 6: Evaluation of conservation of specific biological species) When the purpose is to prove or reject the inclusion of a specific biological species in a drug, pesticide, food, etc., the disclosed technology can be used to detect and select a specific organism from a gel capsule containing an amplified polynucleotide, thereby indicating its content. In addition, detailed analysis of the obtained genetic information makes it possible to evaluate the degree of identity with a standard at the genome level, storage stability, etc. It is expected to be used for quality assurance of microbial preparations, etc.
[0118] Specifically, the procedure involves (1) performing a homology search of gene sequences from a single organism using BLAST or hmmer for the target gene, or (2) mapping of sequence data from a single organism using BWA or bowtie2 to detect differences between the gene sequence from a single organism and the target gene sequence, and identifying genetic mutations.
[0119] (Example 7: Detection of specific biological species) The analysis sample may be feces, saliva, sputum, swabs from the skin, oral cavity, nasal cavity, ears, genitals, etc., surgical washings, tissue extracts, blood, etc., and the presence of one or more specific microorganisms may be detected to determine drug efficacy and drug resistance or evaluate the metabolic ability of food. By using the disclosed technology, it is possible to detect and select specific organisms from gel capsules containing amplified polynucleotides, thereby indicating their content. In addition, by analyzing the obtained genetic information in detail, it is possible to estimate the function and storage stability at the genome level.
[0120] For example, when single-cell sequence data of mouse intestinal microorganisms are obtained, a homology search of single-organism gene sequences can be performed based on genes that metabolize dietary fiber inulin or gene markers that identify the microbial Bacteroides species, to identify the microorganisms and gene groups responsible for decomposing the food inulin, and their functions can be estimated from the homology of known genes and three-dimensional structure prediction based on amino acid sequences. It was also possible to evaluate the proportion (content) of the microbial species in the single-cell sequence data of multiple intestinal microorganisms.
[0121] Example 8: Evaluation of soil bacteria When soil or seawater is used as the analysis sample, the technology disclosed herein can be used to detect and select various specific organisms living in soil or seawater from gel capsules containing amplified polynucleotides, thereby identifying their habitat and indicating their population. In addition, detailed analysis of the obtained genetic information can be used to evaluate at the genome level cultivated varieties, livestock or aquaculture varieties, etc. that are suitable for the soil or seawater. It is also expected that the technology will be used in pesticide-free manufacturing methods using soil bacteria or marine bacteria.
[0122] Specifically, 10 g of soil was collected in a 50 mL tube (2342-050, Iwaki) (n=3), and phosphate-buffered saline (DPBS) (Dulbecco's Phosphate-Buffered Saline, 14190-144, Thermo Fisher Scientific) was added to a total volume of 40 mL to thoroughly suspend the soil. After the suspension, the tube was left on ice for 5 minutes, and the supernatant was transferred to a new 50 mL tube. The supernatant was filtered using a 5 μm filter (SMWP04700, Sigma-Aldrich), centrifuged at 10,000 × g for 5 minutes (75004263, Thermo Fisher Scientific), and the supernatant was removed. The pellet was resuspended in 10 mL of PBS, dispensed in 1 mL portions into 1.5 mL tubes (MCT-150-C, Axygen), and centrifuged at 10,000 × g for 5 minutes to collect the soil bacteria. The bacterial pellets were collected in a single 1.5 mL tube, washed twice with PBS by centrifugation, and then suspended in PBS to obtain a soil bacterial cell suspension. The cell concentration in the prepared cell suspension was measured (microscope: CKX41, OLYMPUS, bacterial counting chamber A161, 2-5679-01, AS ONE), and ultra-low melting point agarose (A5030-10G, Sigma-Aldrich) was added to a final concentration of 1.5% to prepare the soil bacterial suspension to be used for gel capsule production (final cell concentration: 1.5 × 10 3 Next, analysis was carried out in the same manner as in Example 1 or 2, and evaluation was performed.
[0123] (Example 9: Analysis of aquatic microbial composition) In the experiment, 4 L of seawater or freshwater was collected in a sterilized plastic tank, filtered through a 5 μm filter (SMWP04700, Sigma-Aldrich), and then filtered through a 0.22 μm filter (GSWP04700, Sigma-Aldrich) to trap the bacterial fraction on the filter. The 0.22 μm filter was placed in a 25 mL tube (2362-025, Iwaki) containing 10 mL of phosphate-buffered saline (DPBS) (Dulbecco's Phosphate-Buffered Saline, 14190-144, Thermo Fisher Scientific) and thoroughly suspended. The 10 mL of bacterial suspension was dispensed into 1.5 mL tubes (MCT-150-C, Axygen), and the bacteria from the seawater or freshwater were collected by centrifugation at 10,000 × g for 5 minutes. The bacterial pellets were collected in a single 1.5 mL tube, washed twice with PBS by centrifugation, and then suspended in PBS to obtain a cell suspension of bacteria derived from seawater or freshwater. The cell concentration in the prepared cell suspension was measured (microscope: CKX41, OLYMPUS, bacterial counting chamber A161, 2-5679-01, AS ONE), and ultra-low melting point agarose (A5030-10G, Sigma-Aldrich) was added to a final concentration of 1.5% to prepare a bacterial suspension derived from seawater or freshwater for use in making gel capsules (final cell concentration: 1.5 × 10 3 Next, analysis was carried out in the same manner as in Example 1 or 2, and evaluation was performed.
[0124] (Note) As described above, the present disclosure has been illustrated using a preferred embodiment of the present disclosure, but the present disclosure should not be interpreted as being limited to this embodiment. It is understood that the scope of the present disclosure should be interpreted only by the scope of the claims. It is understood that a person skilled in the art can implement an equivalent scope based on the description of the present disclosure and technical common sense from the description of the specific preferred embodiment of the present disclosure. It is understood that the patents, patent applications and literature cited in this specification should be incorporated by reference to this specification as if the contents themselves were specifically described in this specification. This application claims priority to patent application 2019-85836 filed on April 26, 2019 with the Japan Patent Office, and it is understood that the contents of the application itself should be incorporated by reference to this specification as if the contents were specifically described in this specification. [Industrial Applicability]
[0125] The present disclosure can be used in fields such as biological research, medicine, the environment, and health care. [Sequence List Free Text]
[0126] SEQ ID NO: 1: Forward primer SEQ ID NO:2: Reverse primer
Claims
1. 1. A method for analyzing a microbiota composition, comprising:
1. A method comprising assessing microbiota composition from a sample comprising amplified nucleic acid from each cell in the microbiota, amplified nucleic acid from each of the cells, Using a sample containing a microbiota, encapsulating cells one by one in a droplet; gelling the droplets to form gel capsules; immersing said gel capsule in one or more lysis reagents to lyse said cells, wherein a polynucleotide comprising said genomic DNA or a portion thereof is dissolved in said gel capsule and is retained in said gel capsule in a state where substances binding to said genomic DNA or a portion thereof have been removed; contacting the polynucleotide with an amplification reagent to amplify the polynucleotide within the gel capsule; and The method comprises flowing a suspension of the cells through a microchannel and shearing the suspension with oil to create droplets encapsulating the cells.
2. 2. The method of claim 1, wherein the gel capsule is formed from agarose, acrylamide, PEG, gelatin, sodium alginate, matrigel, collagen, or a photocurable resin.
3. 3. The method of claim 1, wherein the lysis reagent is at least one selected from the group consisting of lysozyme, labiase, yatalase, achromopeptidase, protease, nuclease, zymolyase, chitinase, lysostaphin, mutanolysin, sodium dodecyl sulfate, sodium lauryl sulfate, potassium hydroxide, sodium hydroxide, phenol, chloroform, guanidine hydrochloride, urea, 2-mercaptoethanol, dithiothreitol, TCEP-HCl, sodium cholate, sodium deoxycholate, Triton X-100, Triton X-114, NP-40, Brij-35, Brij-58, Tween 20, Tween 80, octylglucoside, octylthioglucoside, CHAPS, CHAPSO, dodecyl-β-D-maltoside, Nonidet P-40, and Zwittergent 3-12.
4. The method according to any one of claims 1 to 3, characterized in that the gel capsules are hydrogel capsules.
5. The method according to any one of claims 1 to 4, further comprising the step of selecting a sample containing amplified nucleic acid to be analyzed from the samples containing amplified nucleic acid derived from each of the cells.
6. The method according to any one of claims 1 to 5, comprising the step of detecting a nucleic acid having a specific sequence in a sample containing the amplified nucleic acid derived from each of the cells.
7. 7. The method of claim 6, wherein the step of detecting a nucleic acid having a specific sequence comprises amplifying and sequencing the nucleic acid having a specific sequence.
8. The method according to any one of claims 1 to 7, wherein the step of assessing the microbiota composition comprises determining the absolute number of each type of microorganism in the microbiota.
9. The method of any one of claims 1 to 8, further comprising obtaining genomic sequence data for each of the cells in the microbiota from a sample comprising amplified nucleic acid from the cells.
10. The method of claim 9, further comprising the step of selecting genomic sequence data to analyze from the genomic sequence data of each of the cells.
11. The method according to any one of claims 1 to 10, wherein the step of evaluating the microbiota composition comprises comparing gene sequences extracted from de novo assembly data for each microorganism.
12. The method according to any one of claims 1 to 11, wherein the microflora is a bacterial flora.
13. The method of claim 12, wherein the microbiota is the intestinal microbiota.
14. A kit for use in the method of claims 1 to 13, comprising a specimen collection container containing a preservation solution.
15. The kit of claim 14 , wherein the preservation solution comprises guanidine or ethanol.
16. 1. A system for analyzing a microbiota composition, comprising: A sample providing unit that provides a sample containing amplified nucleic acid derived from each cell in the microbiota; a composition evaluation unit that evaluates the composition of the microbiota from a sample containing amplified nucleic acid derived from each cell in the microbiota; Including, The sample providing unit includes: a droplet encapsulation unit that uses a sample containing a microflora and encapsulates cells one by one in a droplet, the droplet encapsulation unit being configured to flow a suspension of the cells into a microchannel and shear the suspension with oil to produce the droplets in which the cells are encapsulated; a gel capsule forming unit that gels the droplets to form gel capsules; a cell lysis unit that lyses cells by immersing the gel capsule in one or more lysis reagents, the gel capsule storing one or more lysis reagents for lysing the cells, the cell lysis unit being configured such that a polynucleotide containing the genomic DNA of the cell or a portion thereof is dissolved in the gel capsule and is retained in the gel capsule in a state in which a substance that binds to the genomic DNA or a portion thereof has been removed; a polynucleotide amplification reagent for amplifying the polynucleotide in a gel capsule; Including, the composition evaluation unit includes a detection reagent or a detection device for detecting a nucleic acid having a specific sequence in a sample containing the amplified nucleic acid derived from each of the cells; The detection reagent or detection device includes a nucleic acid amplification and sequencing device for amplifying and sequencing nucleic acids. system.
17. 20. The system of claim 16, further comprising a specimen collection container containing a preservation fluid.
18. The system according to claim 16 or 17, further comprising a sample selection unit for selecting a sample containing amplified nucleic acid to be analyzed from the samples containing amplified nucleic acid derived from each of the cells.
19. The system according to any one of claims 16 to 18, wherein the composition assessment unit includes a calculation unit that performs a procedure for determining the absolute number of each type of microorganism in the microbiome.
20. The system according to any one of claims 16 to 19, wherein the composition evaluation unit further includes a genome sequence data acquisition unit for acquiring genome sequence data of each of the cells in the microbiome from a sample containing amplified nucleic acid derived from each of the cells.
21. The system according to claim 20 , wherein the composition evaluation unit further includes a data selection unit that selects genome sequence data to be analyzed from the genome sequence data of each of the cells.
22. The system according to any one of claims 16 to 21, wherein the composition evaluation unit includes or introduces a gene sequence extracted from de novo assembly data for each microorganism and has a function of comparing the gene sequence.
Citation Information
Patent Citations
Method and kit for detection of microorganism
JP2008173132A
Microfluidic devices
JP2010506136A
Methods for quantitating DNA using digital multiple displacment amplification
US20160068899A1
MDA using bead oligonucleotide
US20180371525A1
Microfluidic devices and methods of use thereof
WO2007133710A2
